Beigene Ltd (NASDAQ:BGNE) CFO Howard Liang sold 40,000 shares of the business’s stock in a transaction that occurred on Monday, March 19th. The stock was sold at an average price of $160.27, for a total value of $6,410,800.00. Following the completion of the transaction, the chief financial officer now directly owns 15,872 shares in the company, valued at $2,543,805.44. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Howard Liang also recently made the following trade(s):

How to Become a New Pot Stock Millionaire
  • On Friday, March 16th, Howard Liang sold 10,872 shares of Beigene stock. The stock was sold at an average price of $157.07, for a total value of $1,707,665.04.

Beigene stock opened at $177.22 on Thursday. The company has a quick ratio of 6.02, a current ratio of 6.09 and a debt-to-equity ratio of 0.23. Beigene Ltd has a 1 year low of $34.36 and a 1 year high of $182.79. The firm has a market cap of $8,763.77, a P/E ratio of -72.63 and a beta of 0.58.

Beigene (NASDAQ:BGNE) last posted its quarterly earnings data on Wednesday, February 28th. The company reported ($2.19) earnings per share for the quarter, missing the consensus estimate of ($1.79) by ($0.40). The company had revenue of $18.17 million for the quarter, compared to analysts’ expectations of $23.00 million. analysts expect that Beigene Ltd will post -7.69 earnings per share for the current fiscal year.

A number of hedge funds have recently bought and sold shares of BGNE. Quantbot Technologies LP bought a new position in Beigene in the 3rd quarter worth approximately $160,000. Tower Research Capital LLC TRC bought a new position in Beigene in the 4th quarter worth approximately $182,000. Comerica Bank bought a new position in Beigene in the 4th quarter worth approximately $246,000. Teachers Retirement System of The State of Kentucky bought a new position in Beigene in the 3rd quarter worth approximately $248,000. Finally, Mackenzie Financial Corp bought a new position in Beigene in the 4th quarter worth approximately $250,000. Hedge funds and other institutional investors own 51.47% of the company’s stock.

Several research analysts have recently commented on the company. Maxim Group set a $120.00 target price on Beigene and gave the stock a “buy” rating in a report on Monday, January 22nd. Morgan Stanley reissued an “overweight” rating and issued a $200.00 target price (up from $93.00) on shares of Beigene in a report on Wednesday. Cowen reissued a “buy” rating on shares of Beigene in a report on Monday, January 8th. Ladenburg Thalmann Financial Services reissued a “buy” rating and issued a $172.00 target price on shares of Beigene in a report on Thursday, March 1st. They noted that the move was a valuation call. Finally, Zacks Investment Research downgraded Beigene from a “hold” rating to a “sell” rating in a report on Monday, January 8th. Three equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Beigene presently has a consensus rating of “Buy” and a consensus target price of $145.17.

WARNING: “Howard Liang Sells 40,000 Shares of Beigene Ltd (BGNE) Stock” was first published by Watch List News and is the property of of Watch List News. If you are reading this article on another domain, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this article can be read at https://www.watchlistnews.com/howard-liang-sells-40000-shares-of-beigene-ltd-bgne-stock/1955120.html.

About Beigene

BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.

Insider Buying and Selling by Quarter for Beigene (NASDAQ:BGNE)

Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.